Insider Trading March 30, 2026

Hercules Capital Director Acquires $105,000 in Stock as Dividend Yield Remains Elevated

Director Loo Wade elects stock compensation, adding to direct and trust holdings amid NAV uptick, financing moves and analyst scrutiny

By Hana Yamamoto HTGC
Hercules Capital Director Acquires $105,000 in Stock as Dividend Yield Remains Elevated
HTGC

Hercules Capital director Loo Wade purchased 7,317 shares of HTGC on March 26, 2026, paying an average of $14.35 per share for a total of $104,998. The buy came while the stock traded near a 52-week low and follows company disclosures of a modest NAV increase and new conditional financing activity. The firm also faces an analyst downgrade and a short report questioning software loan valuations and dividend durability.

Key Points

  • Director Loo Wade bought 7,317 shares of Hercules Capital on March 26, 2026, at an average price of $14.35 per share, totaling $104,998.
  • Hercules Capital reported a projected NAV per share of $12.10 to $12.16 as of December 31, 2025, up from $12.05 at the end of September, and is involved in conditional financing for Savara and a $75 million royalty financing with RTW.
  • The company faces analyst downgrade and short-seller scrutiny due to roughly 35% exposure to software loans; Piper Sandler downgraded the stock and Hunterbrook published a report questioning software debt valuations and dividend sustainability.

Hercules Capital, Inc. (NASDAQ: HTGC) saw a director-level stock purchase on March 26, 2026, when director Loo Wade acquired 7,317 common shares at an average price of $14.35, representing a total transaction value of $104,998. The reported per-share execution range for the transaction was $14.31 to $14.39.

The purchase took place as the shares were trading close to their 52-week low of $13.70 and roughly 22% below the year-to-date level. Following the transaction, Mr. Loo directly holds 14,050 shares and also has an indirect holding of 32,767 shares through the Loo Revocable Trust.


Compensation election and dividend backdrop

The newly acquired shares were purchased pursuant to Mr. Loo's election to receive stock in lieu of cash compensation. Hercules Capital currently offers a dividend yield of 13.24%, a figure that can make stock-based compensation options more attractive for recipients. The company has paid dividends for 22 consecutive years, a continuity referenced in recent reporting.


Recent corporate disclosures and financing activity

Hercules Capital provided preliminary fourth-quarter and year-end estimates indicating an increase in net asset value (NAV) per share. NAV as of December 31, 2025, is projected to be between $12.10 and $12.16, up from $12.05 at the end of September.

The firm is also executing financing arrangements tied to portfolio companies. Hercules amended a loan agreement with Savara Inc., under which it could provide up to an additional $75 million in funding contingent on FDA approval of Savara's investigational therapy. That potential commitment forms part of a broader financing approach that includes a $75 million royalty financing deal with RTW.


Analyst action and short report

Market watchers have flagged risks tied to Hercules Capital's exposure to software-related loans. Piper Sandler downgraded the stock from Overweight to Neutral, citing concerns over roughly 35% of the company's loan portfolio being exposed to the software sector and potential disruption risks associated with artificial intelligence. Separately, a short report from Hunterbrook questioned the valuation of software debt in the portfolio and the sustainability of the dividend. That report highlighted that about 35% of Hercules Capital's loan book is exposed to software debt that, according to the report, is marked at full value despite industry headwinds. Hunterbrook Capital disclosed a short position in Hercules Capital while holding long positions in comparable securities.


Context and takeaway

The director purchase increases Mr. Loo's direct and indirect holdings in Hercules Capital at a time of competing signals: a small NAV uptick and active financing arrangements on one hand, and analyst downgrades plus critical short-seller scrutiny on the other. The timing of stock-based compensation elections and a high stated dividend yield are notable elements in the transaction's rationale.

Risks

  • Concentration risk in the software sector - approximately 35% of Hercules Capital's loan portfolio is exposed to software debt, a sector cited as vulnerable to disruption.
  • Valuation and dividend sustainability concerns - a short report raised questions about software debt being marked at full value and the durability of the company's dividend.
  • Regulatory and clinical contingencies - additional funding commitments to Savara are contingent upon FDA approval of an investigational therapy, creating execution risk tied to clinical and regulatory outcomes.

More from Insider Trading

Photronics Director Sells $204k in PLAB, Exercises Options and Retains Majority Stake Mar 30, 2026 Impact Biomedical CFO Disposes $25,330 in IBO Shares Across Two Trades Mar 30, 2026 Control Empresarial trims Talos Energy stake with $38.54 million share sale Mar 30, 2026 Advanced Flower Capital Director Increases Stake with $62,475 Purchase Mar 30, 2026 PBF Energy SVP Sells $2.57M in Stock After Exercising Long‑standing Options Mar 30, 2026